Rise and shine, everyone, the middle of the week is already here. But time waits for no one, of course. Meanwhile, a hazy, muggy morning is unfolding here on the Pharmalot campus, where the officials mascot is noisily snoozing in a corner and the short people are preoccupied, as they should be. As for us, we are downing yet another needed cup of stimulation. Feel free to join us, as always. And here are some tidbits to help you along. Have a wonderful day and keep in touch. …
A trio of key White House advisers hinted for the first time that they could support a progressive proposal to cap price increases for certain medicines, speaking at a closed-door Capitol Hill briefing of Republican senators, STAT reports. The administration’s openness to the idea — which has not yet earned formal support of many Democrats, let alone Republicans — serves as the latest evidence that the Trump administration has become increasingly reliant on Capitol Hill for a victory on drug costs and, perhaps, increasingly pliable on policy.
With pharma abandoning antibiotics R&D and resistant infections on the rise, the U.K. launched a payment system to spur development of new drugs, Pharmaphorum says. A new subscription approach will pay companies upfront for access to new antibiotics based on their value to the National Health Service, rather than the volume of medicines sold. The hope is this will give companies that develop innovative antimicrobials a greater return on their investment than if the drugs are held in reserve for resistant infections and used only sparingly.
About the Author Reprints
